CP-91149

Brand

No Brand

Description

CP-91149 is a human liver glycogen phosphorylase α (HLGPα) inhibitor with an IC50 of 0.13 μM in the presence of 7.5 mM glucose. CP-91149 suppressed glucagon-triggered glycogenolysis in isolated rat hepatocytes and in primary human hepatocytes. In vivo, oral injection of CP-91149 to diabetic ob/ob mice at 25–50 mg/kg led in rapid (3 h) glucose lowering by 100–120 mg/dl without producing hypoglycemia. In addition, upon treatment with CP-91149, A549 non-small cell lung carcinoma (NSCLC) cells accumulated glycogen with associated growth retardation. Treated normal skin fibroblasts also accumulated glycogen with G1-cell cycle arrest that was associated with inhibition of cyclin E-CDK2 activity. Overall, cells expressing high levels of brain GP were growth prevented by CP-91149 associating with glycogen accumulation whereas cells expressing low levels of brain GP were not affected by the agent.

Application

Reactivity

Photos